Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy | |
He, Yaping1,2; Xiong, Ting1,3; He, Siyu1,4; Sun, Hongyu1,4; Huang, Chenxi1; Ren, Xiaohong1; Wu, Li1; Patterson, Laurence H.5; Zhang, Jiwen1,4,6 | |
刊名 | ADVANCED FUNCTIONAL MATERIALS |
2020-10-07 | |
页码 | 13 |
关键词 | cancer therapy cyclodextrin frameworks low-molecular-weight heparin lung-targeting carriers RGD peptide |
ISSN号 | 1616-301X |
DOI | 10.1002/adfm.202004550 |
通讯作者 | Wu, Li(track_wuly@163.com) ; Patterson, Laurence H.(L.H.Patterson@bradford.ac.uk) ; Zhang, Jiwen(jwzhang@simm.ac.cn) |
英文摘要 | Lung cancer is a serious threat to human health with the highest morbidity and mortality; metastatic lung cancer accounts for a majority of cancer-related deaths. Hence, there is considerable interest in developing efficient lung-targeted drug delivery systems to improve overall survival and quality of life of lung cancer patients. Based on the lung-targeting characteristics of cubic crosslinked cyclodextrin metal-organic framework (CDF) nanoparticles, this study shows the synthesis of a nanoplatform using RGD-functionalized CDF to co-deliver low-molecular-weight heparin (LMWH) and doxorubicin (DOX) for treatment of lung cancer. Rational design of the DOX-loaded RGD-CDF-LMWH nanoplatform (RCLD) is carried out. RCLD nanoparticles are efficiently targeted to lung tumors following intravenous administration; RCLD accumulation in the lung is 5.8 times greater than that in the liver. Moreover, RCLD inhibits migration and invasion of cancer cells in vitro and significantly diminishes lung tumor nodule count and area of spread in human A549 and murine B16F10 lung cancer models in vivo. Furthermore, RCLD does not show serum enzyme or histopathologic indicators of tissue damage or adverse hematologic effects. Therefore, the multiple antitumor activities of this novel RCLD nanoplatform, alongside its safety profile for normal tissues, strongly support its use for targeted treatment of lung cancer. |
资助项目 | Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12050307] ; Key Program for International Science and Technology Cooperation Projects of China[2020YFE0201700] ; National Science and Technology Major Projects for Major New Drugs Innovation and Development[2018ZX09721002-009] ; National Nature Science Foundation of China[81773645] |
WOS关键词 | DELIVERY-SYSTEMS ; PROTEIN CORONA ; DRUG-DELIVERY ; NANOPARTICLES ; MICROSPHERES ; POLYMER ; DOXORUBICIN ; METASTASIS ; STABILITY ; INTEGRINS |
WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics |
语种 | 英语 |
出版者 | WILEY-V C H VERLAG GMBH |
WOS记录号 | WOS:000575813300001 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/291337] |
专题 | 中国科学院上海药物研究所 |
通讯作者 | Wu, Li; Patterson, Laurence H.; Zhang, Jiwen |
作者单位 | 1.Chinese Acad Sci, Ctr Drug Delivery Syst, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 2.Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou 450052, Peoples R China 3.Jiangxi Univ Tradit Chinese Med, Key Lab Modern Preparat TCM, Minist Educ, Nanchang 330004, Jiangxi, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 5.Univ Bradford, Fac Life Sci, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England 6.Natl Inst Food & Drug Control, NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Beijing 100050, Peoples R China |
推荐引用方式 GB/T 7714 | He, Yaping,Xiong, Ting,He, Siyu,et al. Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy[J]. ADVANCED FUNCTIONAL MATERIALS,2020:13. |
APA | He, Yaping.,Xiong, Ting.,He, Siyu.,Sun, Hongyu.,Huang, Chenxi.,...&Zhang, Jiwen.(2020).Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy.ADVANCED FUNCTIONAL MATERIALS,13. |
MLA | He, Yaping,et al."Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy".ADVANCED FUNCTIONAL MATERIALS (2020):13. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论